Skip to main content
Friday 11 July 2025
BlueSky linkedin youtube rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • Axtria Ignite 2025
    • LS Industry Report 2025
    • Frontiers Health 2024
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
BlueSky linkedin rss
Sign in

generic

News
Merck to spin old drugs into ‘NewCo’ focused on generics, women’s health

Merck to spin old drugs into ‘NewCo’ focused on generics, wo...

News
Old typewriter patent stamp. OCTOBER 1894

Lilly claims another victory in Alimta patent defence

News
Lungs-16-9

Chasing Mylan, Hikma tries again with rejected generic Advai...

News
Takeda nets $660m from product selloff to Germany’s Stada

Takeda nets $660m from product selloff to Germany’s Stada

News
Medical vials and Syringe, Isolated on Blue background

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimt...

News
Epipen

Hikma buys potential Epipen rival from troubled Insys

UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi

  • Load more results

Editor's Picks

  1. AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline
  2. Summit climbs on rumour of $15bn AstraZeneca interest
  3. The NHS 10 Year Plan arrives – what are the highlights?
  4. Shionogi puts up to $600m behind BioVersys antibiotics
  5. The US Senate has passed Trump's budget – what comes next?
News
Just how radical is the FDA's complete response letter move?

Just how radical is the FDA's complete response letter move?

The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.

Market Access
pharmaphorum podcast Episode 178a - Sandra Anderson and Chris Williams, Cencora

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • ASCO 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company